Laryngomalacia Study
- Registration Number
- NCT01782560
- Lead Sponsor
- Children's & Women's Health Centre of British Columbia
- Brief Summary
Noisy breathing is commonly caused by a floppy voicebox which is a condition called laryngomalacia. The cause of laryngomalacia is not fully understood, but some studies have suggested that it could be due to acid escaping from the stomach and spreading up the swallowing passage to the throat (acid reflux). This affects about 1 in 100 newborns and is therefore one of the most common reasons for infants to see Otolaryngologists at BC Children's Hospital (BCCH). These infants can have a spectrum of distressing symptoms including squeaky breathing, choking, difficulty feeding, failure to gain weight, and episodes of turning blue (due to lack of oxygen).
At present, Otolaryngologists at BCCH will sometimes give children with laryngomalacia medication to reduce the amount of acid they make in their stomachs, in the hope that this will reduce their symptoms of laryngomalacia. It has never been scientifically confirmed whether anti-reflux medication will benefit these children any more than doing nothing at all.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- children less than 1 years old
- children determined that they have laryngomalacia at the Pediatric Otolaryngology clinic at BC Children's Hospital.
Children cannot participate in this study if they have:
- those already on anti-reflux medicine and considered medically unsafe to go through the washout period;
- allergy to the trial medications;
- nasogastric or permanent feeding tube;
- other laryngeal abnormalities.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Two different placebo formulations will be created which will designed to be identical in appearance, taste, and consistency to the two study medications. Omeprazole Omeprazole Omeprazole (a proton-pump inhibitor) is the most common treatment given to infants with laryngomalacia, in the hope that this will reduce their symptoms. Although this is an effective anti-reflux medication in this population, its use is off-label, and like any medication has potential risks, particularly in very young children. 2 mg/kg/day omeprazole.
- Primary Outcome Measures
Name Time Method Laryngomalacia Symptom Score Change from baseline and at end of study (baseline and 8 weeks) This score is a disease-specific quality of life measure for laryngomalacia. Each of the symptoms that can occur in laryngomalacia are scored as present (1) or absent (0) as follows - inspiratory stridor, suprasternal retraction, substernal retraction, feeding difficulty, choking, post-feeding vomit, failure to thrive (i.e. poor weight gain with deviation from the normal growth curve), and cyanosis. Therefore for each patient, a total symptom score is calculated (8 = all symptoms, 0 = no symptoms).
- Secondary Outcome Measures
Name Time Method End of treatment 24-hour double-probe pH monitoring Change from baseline and at end of study (baseline and 8 weeks) Caring For a Child with Laryngomalacia Family Impact Questionnaire Change from baseline and at end of study (baseline and 8 weeks) Revised Infant Gastro-Esophageal Reflux Questionnaire Change from baseline and at end of study (baseline and 8 weeks) Reflux Finding Score Change from baseline and at end of study (baseline and 8 weeks) Weight Change from baseline, to half-way point and at end of study (baseline, 4 weeks and 8 weeks)
Trial Locations
- Locations (1)
BC Children's Hospital
🇨🇦Vancouver, British Columbia, Canada